World Heart seeks US OK for LVAS (left ventricular assist system) conduit:
This article was originally published in Clinica
World Heart has submitted a supplemental premarket approval application to the US FDA for permission to use its ePTFE inflow conduit as an alternative option for its Novacor left ventricular assist system (LVAS). European clinical trials of an earlier version of the conduit showed that it was linked with a reduction in stroke rate and that "many clinicians" preferred using it, said the Ottawa, Canada firm. The latest version of the conduit has undergone several design refinements and is already approved in Europe, the company added.
You may also be interested in...
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.